

Original Research Article

Comparative Evaluation of Choroidal Thickness between Hypertensives and Healthy Controls: An Oct Based Study

Dr Lavanyaah Anandamurugan^{1*}, Dr Sujatha V², Dr Pallavi BA³.

^{1*}Department of ophthalmology, PG, MVJ Medical College and Research Hospital.

²Department of ophthalmology, MBBS MS OPHTHALMOLOGY (PROFESSOR AND HOD), MVJ Medical College and Research Hospital.

³Professor, Department of Ophthalmology, MBBS DOMS DNB OPHTHALMOLOGY.

Corresponding Author: Dr Lavanyaah Anandamurugan

Department of ophthalmology, PG, MVJ Medical College and Research Hospital.

Email: lavu11998@gmail.com

Orchid: 0009-0007-4368-7622

Received: 15.06.26, Revised: 21.06.26, Accepted: 29.06.26

ABSTRACT

Purpose: To compare choroidal thickness in patients with systemic hypertension and age-matched healthy individuals using spectral-domain optical coherence tomography (SD-OCT).

Methods: This prospective cross-sectional comparative study included 70 participants, comprising 35 hypertensive patients and 35 healthy controls aged 40-60 years. Choroidal thickness was measured using enhanced depth imaging SD-OCT at the subfoveal region and at 500 μ m nasal and temporal to the fovea. Independent t-test was used for intergroup comparison, and correlation analysis was performed to assess association with blood pressure.

Results: Subfoveal choroidal thickness did not show a statistically significant difference between the two groups. However, nasal and temporal choroidal thickness were significantly reduced in hypertensive patients compared to controls ($p < 0.05$).

Conclusion: Systemic hypertension is associated with regional thinning of the choroid, predominantly in the nasal and temporal regions, while the subfoveal region remains relatively preserved. SD-OCT serves as a useful non-invasive tool for detecting hypertensive choroidal changes.

Keywords: Choroidal Thickness, Hypertension, Optical Coherence Tomography, Sd-Oct, Choroid, Hypertensive Retinopathy.

INTRODUCTION

Systemic hypertension is a major global health concern and is known to cause significant microvascular alterations affecting multiple organs, including the eye. Ocular manifestations include hypertensive retinopathy, optic neuropathy, and choroidopathy.¹

The choroid plays a crucial role in maintaining outer retinal function by supplying oxygen and nutrients to the retinal pigment epithelium and photoreceptors.² Chronic hypertension may lead to vascular sclerosis, reduced perfusion, and structural alterations in the choroidal vasculature.

With the advent of spectral-domain optical coherence tomography (SD-OCT) and enhanced depth imaging, in vivo assessment of choroidal thickness has become possible.³ Choroidal thickness has emerged as an

important biomarker reflecting systemic vascular health.

This study was conducted to evaluate and compare choroidal thickness in hypertensive patients and healthy individuals using SD-OCT.

MATERIALS AND METHODS

This prospective cross-sectional comparative study was conducted in the Department of Ophthalmology, MVJ Medical College and Hospital, over a period of six months.

A total of 70 participants were included and divided into two groups:

- Group 1: 35 patients with systemic hypertension
- Group 2: 35 age-matched healthy controls

Inclusion Criteria

- Age between 40 and 60 years
- Diagnosed essential hypertension (SBP >140 mmHg and DBP >90 mmHg)
- Clear ocular media

Exclusion Criteria

- Diabetes mellitus
- Glaucoma
- Refractive error greater than ± 3 diopters
- History of ocular surgery
- Macular pathology

All participants underwent comprehensive ophthalmic examination.

Choroidal thickness was measured using spectral-domain OCT with enhanced depth imaging.

Measurements were taken at:

- Subfoveal region
- 500 μm nasal to fovea
- 500 μm temporal to fovea

Statistical Analysis

Data were analysed using:

- Independent t-test
- Correlation test

P value < 0.05 was considered statistically significant.

RESULTS

The mean subfoveal choroidal thickness did not differ significantly between hypertensive patients and healthy controls ($p > 0.05$).

However, nasal and temporal choroidal thickness were significantly reduced in hypertensive individuals compared to controls ($p < 0.05$).

Pearson correlation analysis demonstrated a negative correlation between blood pressure levels and choroidal thickness.

DISCUSSION

This study demonstrated a significant reduction in nasal and temporal choroidal thickness in hypertensive patients, while subfoveal thickness remained relatively preserved.^{1,2,3}

These findings are consistent with previous studies by Akay et al.⁴ and Waghmare et al.⁵, who reported similar regional thinning of the choroid in systemic hypertension⁶. Similar

results have been documented by Esmaelpour et al.⁷ and Mrejen and Spaide,⁸ who used OCT-based imaging to demonstrate choroidal structural alterations associated with systemic vascular disease.

The preservation of subfoveal choroidal thickness may be attributed to autoregulatory mechanisms and increased vascular density in the subfoveal region, which help maintain perfusion despite systemic vascular compromise.^{9,10} Spaide et al.¹¹ demonstrated that the subfoveal choroid exhibits unique haemodynamic properties that confer relative resistance to systemic vascular changes.

Chronic hypertension leads to vascular narrowing, sclerosis, and reduced choroidal perfusion, resulting in structural thinning.^{12,13} Bhutto and Luttu¹⁴ described histopathological evidence of choroidal vascular loss and fibrosis in hypertensive eyes, further supporting the OCT-based findings observed in this and similar studies.

These findings suggest that choroidal thickness measurement may serve as a useful biomarker for early detection of hypertensive vascular damage.^{15,16} Gupta et al.¹⁷ and Nickla and Wallman¹⁸ have highlighted the clinical utility of choroidal imaging in monitoring systemic vascular conditions. Furthermore, Regatieri et al.¹⁹ and Margolis and Spaide²⁰ emphasised the reproducibility and reliability of enhanced depth imaging SD-OCT in quantifying choroidal thickness across different patient populations.

CONCLUSION

Systemic hypertension causes regional reduction in choroidal thickness, predominantly affecting nasal and temporal regions.


Subfoveal thickness remains relatively preserved.

Spectral-domain OCT is a valuable non-invasive tool for detecting hypertensive choroidal changes.

Table 1: Comparison of Choroidal Thickness

Region	Controls (μm)	Hypertensive (μm)
Subfoveal	295.86	294.02
Nasal	285.34	256.38
Temporal	280.34	269.53

Figure 1



REFERENCE LIST

1. Philip JA, Solomon CB, Konnakodan SM, et al. Comparative evaluation of choroidal thickness in hypertensive individuals and healthy controls using optical coherence tomography. *Kerala J Ophthalmol.* 2025;37(1):30-33.
2. Tsukikawa M, Stacey AW. A review of hypertensive retinopathy and chorioretinopathy. *Clin Optom (Auckl).* 2020;12:67-73.
3. Wong TY, Mitchell P. The eye in hypertension. *Lancet.* 2007;369:425-435.
4. Papathanasiou KA, Kazantzis D, Vrachatis DA, Giotaki SG, Papaconstantinou E, Kanakis M, Avramides D, Deftereos S, Chatziralli I, Georgalas I. Choroidal thickness in patients with systemic arterial hypertension: a systematic review and meta-analysis. *Therapeutic advances in ophthalmology.* 2022 Nov;14:25158414221132825.
5. Waghmare SR, Mittal S, Pathania M, Samanta R, Kumawat D, Gupta N, et al. Comparison of choroidal thickness in systemic hypertensive subjects with healthy individuals by spectral domain optical coherence tomography. *Indian J Ophthalmol.* 2021;69:1183-1188.
6. Tan KA, Gupta P, Agarwal A, Chhablani J, Cheng CY, Keane PA, et al. State of science: Choroidal thickness and systemic health. *Surv Ophthalmol.* 2016;61:566-581.
7. Esmaelpour M, Povazay B, Hermann B, Hofer B, Kajic V, Kapoor K, et al. Three-dimensional 1060-nm OCT: choroidal thickness maps in normal subjects and improved posterior segment visualization in cataract patients. *Invest Ophthalmol Vis Sci.* 2010;51:5260-5266.
8. Di Staso F, Ciancaglini M, Abdolrahimzadeh S, D'APOLITO FA, Scuderi G. Optical coherence tomography of choroid in common neurological diseases. *in vivo.* 2019 Sep 1;33(5):1403-9.
9. Ramrattan RS, van der Schaft TL, Mooy CM, de Bruijn WC, Mulder PG, de Jong PT. Morphometric analysis of Bruch's membrane, the choriocapillaris, and the choroid in aging. *Invest Ophthalmol Vis Sci.* 1994;35:2857-2864.
10. Spaide RF, Koizumi H, Pozzoni MC. Enhanced depth imaging spectral-domain optical coherence tomography. *Am J Ophthalmol.* 2008;146:496-500.
11. Ikuno Y, Kawaguchi K, Nouchi T, Yasuno Y. Choroidal thickness in healthy Japanese subjects. *Invest Ophthalmol Vis Sci.* 2010;51:2173-2176.
12. Bhutto I, Luty G. Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris complex. *Mol Aspects Med.* 2012;33:295-317.
13. Vascular Endothelium in Human Physiology and Pathophysiology. Vallance P, Webb D, eds. Amsterdam: Harwood Academic; 2000:1-47.

- [Choroidal vascular regulation in hypertension.]
14. Gupta P, Cheung CY, Saw SM, Bhargava M, Tan CS, Tan BB, et al. Peripapillary choroidal thickness in young Asians with high myopia. *Invest Ophthalmol Vis Sci*. 2015;56:1475-1481.
 15. Nickla DL, Wallman J. The multifunctional choroid. *Prog Retin Eye Res*. 2010;29:144-168.
 16. Regatieri CV, Branchini L, Carmody J, Fujimoto JG, Duker JS. Choroidal thickness in patients with diabetic retinopathy analyzed by spectral-domain optical coherence tomography. *Retina*. 2012;32:563-568.
 17. Sezer T, Altınışık M, Koytak İA, Özdemir MH. The choroid and optical coherence tomography. *Turkish journal of ophthalmology*. 2016 Jan 5;46(1):30.
 18. Kur J, Newman EA, Chan-Ling T. Cellular and physiological mechanisms underlying blood flow regulation in the retina and choroid in health and disease. *Prog Retin Eye Res*. 2012;31:377-406.
 19. Mwanza JC, Hochberg JT, Banitt MR, Feuer WJ, Budenz DL. Lack of association between glaucoma and macular choroidal thickness measured with enhanced depth-imaging optical coherence tomography. *Invest Ophthalmol Vis Sci*. 2011;52:3430-3435.
 20. Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD, et al. Retinopathy in diabetes. *Diabetes Care*. 2004;27(Suppl 1):S84-S87.